AAN has issued a practice guideline update for vaccine-preventable infections and immunizations for individuals with multiple sclerosis (MS). A subcommittee of the AAN — tasked with developing, disseminating and implementing these guidelines — found improvements and additions to the recommendations previously issued in 2002.
Predictors of all-cause hospitalizations in patients with MS included increased age, presence of a comorbidity, and having a history of hospital admissions.
The mechanism by which it exerts therapeutic effects in MS is unknown but may involve the reduction of lymphocyte migration into the central nervous system.
The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ofatumumab (Novartis) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults.
More patients with early relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab experienced confirmed disability improvement than disability worsening.
